Recent off-label use of a complement inhibiting drug, eculizumab (CD55 inhibitor) was shown to provide a dramatic benefit in patients with CHAPLE disease with an immediate correction of ...

The efficacy of eculizumab in the treatment of paroxysmal nocturnal hemoglobinuria, which results from complete or substantial loss of the terminal complement inhibitors CD55 and CD59 from the ...

Through this approval, eculizumab becomes a first anti-complement medical therapy indicated for treating two rare conditions- paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic ...

A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the ...

Ultomiris is a longer lasting version of Alexion’s Soliris (eculizumab) complement inhibitor, which has produced “promising” evidence in the clinic through a compassionate use programme ...

See full prescribing information for complete boxed warning. Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis. Life-threatening ...

See full prescribing information for complete boxed warning. Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis. Life-threatening and ...

(NYSE: and TASE: TEVA) announced today that the companies have entered into a license, development and commercialization agreement for EPYSQLI ® (eculizumab ... is a complement inhibitor ...

Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meningitidis. Life-threatening and fatal meningococcal infections have occurred in patients ...

(NYSE: and TASE: TEVA) announced today that the companies have entered into a license, development and commercialization agreement for EPYSQLI ® (eculizumab-aagh), Samsung Bioepis’ biosimilar ...